APA (7th ed.) Citation

Sahebi, F., Eikema, D., Koster, L., Kroger, N., Meijer, E., van Doesum, J. A., . . . Schönland, S. (2021). Post-transplantation cyclophosphamide for graft-versus- host disease prophylaxis in multiple myeloma patients who underwent allogeneic hematopoietic cell transplantation: First comparison by Donor Type. A study from the chronic malignancies working party of the European Society for Blood and Marrow Transplantation. Transplantation and cellular therapy, 27(12), . https://doi.org/10.1016/j.jtct.2021.09.008

Chicago Style (17th ed.) Citation

Sahebi, Firoozeh, et al. "Post-transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation." Transplantation and Cellular Therapy 27, no. 12 (2021). https://doi.org/10.1016/j.jtct.2021.09.008.

MLA (9th ed.) Citation

Sahebi, Firoozeh, et al. "Post-transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation." Transplantation and Cellular Therapy, vol. 27, no. 12, 2021, https://doi.org/10.1016/j.jtct.2021.09.008.